Tushar Garimella
Executive Director, Oncology, Quantitative Clinical Pharmacology Daiichi Sankyo
Seminars
Wednesday 5th November 2025
Exploring Enhertu Dose Optimization & Selection for HER2 Mutant NSCLC Indication
12:00 pm
- Introducing the clinical program for Enhertu in HER2-mutant NSCLC
- Understanding the general principles of ADC dose selection and highlighting lessons learned from Enhertu clinical program
- Breaking down the dose selection and optimization for Enhertu supporting approval in HER2 mutant NSCLC population
